Kesselheim AS - Search Results

1

Efficacy, Safety, and Regulatory Approval of Food and Drug Administration-Designated Breakthrough and Nonbreakthrough Cancer Medicines.

Hwang TJ, Franklin JM, Chen CT, Lauffenburger JC, Gyawali B, Kesselheim AS, Darrow JJ. Hwang TJ, et al. Among authors: kesselheim as. J Clin Oncol. 2018 Jun 20;36(18):1805-1812. doi: 10.1200/JCO.2017.77.1592. Epub 2018 Apr 24. J Clin Oncol. 2018. PMID: 29688832

2

Changing interactions between physician trainees and the pharmaceutical industry: a national survey.

Austad KE, Avorn J, Franklin JM, Kowal MK, Campbell EG, Kesselheim AS. Austad KE, et al. Among authors: kesselheim as. J Gen Intern Med. 2013 Aug;28(8):1064-71. doi: 10.1007/s11606-013-2361-0. J Gen Intern Med. 2013. PMID: 23444007 Free PMC article. Clinical Trial.

3

Speaking the same language? International variations in the safety information accompanying top-selling prescription drugs.

Kesselheim AS, Franklin JM, Avorn J, Duke JD. Kesselheim AS, et al. BMJ Qual Saf. 2013 Sep;22(9):727-34. doi: 10.1136/bmjqs-2012-001704. Epub 2013 Apr 25. BMJ Qual Saf. 2013. PMID: 23620531

4

Distributions of industry payments to Massachusetts physicians.

Kesselheim AS, Robertson CT, Siri K, Batra P, Franklin JM. Kesselheim AS, et al. N Engl J Med. 2013 May 30;368(22):2049-52. doi: 10.1056/NEJMp1302723. Epub 2013 May 1. N Engl J Med. 2013. PMID: 23635021 No abstract available.

5

Physician trainees' interactions with the pharmaceutical industry.

Austad KE, Avorn J, Franklin JM, Kesselheim AS. Austad KE, et al. Among authors: kesselheim as. J Gen Intern Med. 2013 Oct;28(10):1267. doi: 10.1007/s11606-013-2526-x. J Gen Intern Med. 2013. PMID: 23797922 Free PMC article. No abstract available.

6

Clinical and regulatory features of drugs not initially approved by the FDA.

Wang B, Avorn J, Kesselheim AS. Wang B, et al. Among authors: kesselheim as. Clin Pharmacol Ther. 2013 Dec;94(6):670-7. doi: 10.1038/clpt.2013.165. Epub 2013 Aug 20. Clin Pharmacol Ther. 2013. PMID: 23963252 Review.

7

Approval and withdrawal of new antibiotics and other antiinfectives in the U.S., 1980-2009.

Outterson K, Powers JH, Seoane-Vazquez E, Rodriguez-Monguio R, Kesselheim AS. Outterson K, et al. Among authors: kesselheim as. J Law Med Ethics. 2013 Fall;41(3):688-96. doi: 10.1111/jlme.12079. J Law Med Ethics. 2013. PMID: 24088160

8

Assessment of US pathway for approving medical devices for rare conditions.

Hwang TJ, Carpenter D, Kesselheim AS. Hwang TJ, et al. Among authors: kesselheim as. BMJ. 2014 Jan 17;348:g217. doi: 10.1136/bmj.g217. BMJ. 2014. PMID: 24443478 Review. No abstract available.

9

Quantifying The Food And Drug Administration's rulemaking delays highlights the need for transparency.

Hwang TJ, Avorn J, Carpenter D, Kesselheim AS. Hwang TJ, et al. Among authors: kesselheim as. Health Aff (Millwood). 2014 Feb;33(2):309-15. doi: 10.1377/hlthaff.2013.0564. Health Aff (Millwood). 2014. PMID: 24493775

10

New FDA breakthrough-drug category--implications for patients.

Darrow JJ, Avorn J, Kesselheim AS. Darrow JJ, et al. Among authors: kesselheim as. N Engl J Med. 2014 Mar 27;370(13):1252-8. doi: 10.1056/NEJMhle1311493. N Engl J Med. 2014. PMID: 24670173 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

718 results

Search Page